Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis.
Adult
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
/ complications
Antibodies, Antineutrophil Cytoplasmic
/ adverse effects
Antigens, CD
/ urine
Antigens, Differentiation, Myelomonocytic
/ urine
Biomarkers
/ urine
Chemokine CCL2
/ urine
Female
Humans
Kidney Diseases
/ diagnosis
Longitudinal Studies
Male
Middle Aged
Receptors, Cell Surface
Urinalysis
ANCA
CD163
MCP-1
biomarkers
vasculitis
Journal
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402
Informations de publication
Date de publication:
01 02 2020
01 02 2020
Historique:
received:
12
04
2018
accepted:
18
08
2018
pubmed:
1
11
2018
medline:
12
9
2020
entrez:
1
11
2018
Statut:
ppublish
Résumé
Prior work has shown that urinary soluble CD163 (usCD163) displays excellent biomarker characteristics for detection of active renal vasculitis using samples that included new diagnoses with highly active renal disease. This study focused on the use of usCD163 in the detection of the more clinically relevant state of mild renal flare and compared results of usCD163 testing directly to testing of urinary monocyte chemoattractant protein-1 (uMCP-1). Patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV, n = 88) were identified within a serially sampled, longitudinal and multicentre cohort. Creatinine-normalized usCD163 and uMCP-1 levels were measured by enzyme-linked immunosorbent assay and, both alone and in combination, were compared between times of active renal AAV and during remission and/or active non-renal AAV. Samples from 320 study visits included times of active renal vasculitis (n = 39), remission (n = 233) and active extrarenal vasculitis (n = 48). Median creatinine levels were 0.9 mg/dL [interquartile range (IQR) 0.8-1.2] in remission and 1.4 mg/dL (IQR 1.0-1.8) during renal flare. usCD163 levels were higher in patients with active renal vasculitis compared with patients in remission and those with active extrarenal vasculitis, with median values of 162 ng/mmol (IQR 79-337), 44 (17-104) and 38 (7-76), respectively (P < 0.001). uMCP-1 levels were also higher in patients with active renal vasculitis compared with patients in remission and those with active extrarenal vasculitis, with median values of 10.6 pg/mmol (IQR 4.6-23.5), 4.1 (2.5-8.4) and 4.1 (1.9-6.8), respectively (P < 0.001). The proposed diagnostic cut-points for usCD163 and uMCP-1 were 72.9 ng/mmol and 10.0 pg/mmol, respectively. usCD163 and uMCP-1 levels were marginally correlated (r2 = 0.11, P < 0.001). Combining novel and existing biomarkers using recursive tree partitioning indicated that elevated usCD163 plus either elevated uMCP-1 or new/worse proteinuria improved the positive likelihood ratio (PLR) of active renal vasculitis to 19.2. A combination of usCD163 and uMCP-1 measurements appears to be useful in identifying the diagnosis of subtle renal vasculitis flare.
Sections du résumé
BACKGROUND
Prior work has shown that urinary soluble CD163 (usCD163) displays excellent biomarker characteristics for detection of active renal vasculitis using samples that included new diagnoses with highly active renal disease. This study focused on the use of usCD163 in the detection of the more clinically relevant state of mild renal flare and compared results of usCD163 testing directly to testing of urinary monocyte chemoattractant protein-1 (uMCP-1).
METHODS
Patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV, n = 88) were identified within a serially sampled, longitudinal and multicentre cohort. Creatinine-normalized usCD163 and uMCP-1 levels were measured by enzyme-linked immunosorbent assay and, both alone and in combination, were compared between times of active renal AAV and during remission and/or active non-renal AAV.
RESULTS
Samples from 320 study visits included times of active renal vasculitis (n = 39), remission (n = 233) and active extrarenal vasculitis (n = 48). Median creatinine levels were 0.9 mg/dL [interquartile range (IQR) 0.8-1.2] in remission and 1.4 mg/dL (IQR 1.0-1.8) during renal flare. usCD163 levels were higher in patients with active renal vasculitis compared with patients in remission and those with active extrarenal vasculitis, with median values of 162 ng/mmol (IQR 79-337), 44 (17-104) and 38 (7-76), respectively (P < 0.001). uMCP-1 levels were also higher in patients with active renal vasculitis compared with patients in remission and those with active extrarenal vasculitis, with median values of 10.6 pg/mmol (IQR 4.6-23.5), 4.1 (2.5-8.4) and 4.1 (1.9-6.8), respectively (P < 0.001). The proposed diagnostic cut-points for usCD163 and uMCP-1 were 72.9 ng/mmol and 10.0 pg/mmol, respectively. usCD163 and uMCP-1 levels were marginally correlated (r2 = 0.11, P < 0.001). Combining novel and existing biomarkers using recursive tree partitioning indicated that elevated usCD163 plus either elevated uMCP-1 or new/worse proteinuria improved the positive likelihood ratio (PLR) of active renal vasculitis to 19.2.
CONCLUSION
A combination of usCD163 and uMCP-1 measurements appears to be useful in identifying the diagnosis of subtle renal vasculitis flare.
Identifiants
pubmed: 30380100
pii: 5151289
doi: 10.1093/ndt/gfy300
pmc: PMC8205505
doi:
Substances chimiques
Antibodies, Antineutrophil Cytoplasmic
0
Antigens, CD
0
Antigens, Differentiation, Myelomonocytic
0
Biomarkers
0
CCL2 protein, human
0
CD163 antigen
0
Chemokine CCL2
0
Receptors, Cell Surface
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
283-291Subventions
Organisme : NCATS NIH HHS
ID : U2C TR002818
Pays : United States
Organisme : NCRR NIH HHS
ID : U54 RR019497
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
Références
J Am Soc Nephrol. 2000 Nov;11(11):2036-2043
pubmed: 11053479
Ann Rheum Dis. 2010 Jun;69(6):1036-43
pubmed: 19574233
Ann Intern Med. 1999 Mar 16;130(6):461-70
pubmed: 10075613
J Leukoc Biol. 2010 Dec;88(6):1201-5
pubmed: 20807704
Nephrol Dial Transplant. 2016 Dec;31(12):1970-1972
pubmed: 27358273
Ann Rheum Dis. 2009 Dec;68(12):1827-32
pubmed: 19054820
Nephrol Dial Transplant. 2016 Dec;31(12):2023-2033
pubmed: 27242373
Scand J Clin Lab Invest. 2012 Feb;72(1):1-13
pubmed: 22060747
Am J Nephrol. 2016;43(2):112-9
pubmed: 27003681
Clin J Am Soc Nephrol. 2015 Jan 7;10(1):54-62
pubmed: 25516918
J Am Soc Nephrol. 2016 Sep;27(9):2906-16
pubmed: 26940094
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
J Rheumatol. 2013 May;40(5):674-83
pubmed: 23547217
Nephrol Dial Transplant. 2004 Nov;19(11):2761-8
pubmed: 15353578
Am J Pathol. 2005 Nov;167(5):1207-19
pubmed: 16251406